345 related articles for article (PubMed ID: 25785610)
1. Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.
Schwalbe B; Schreiber M
PLoS One; 2015; 10(3):e0119879. PubMed ID: 25785610
[TBL] [Abstract][Full Text] [Related]
2. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
3. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
4. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
[TBL] [Abstract][Full Text] [Related]
5. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
6. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
7. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
Platt EJ; Kuhmann SE; Rose PP; Kabat D
J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
[TBL] [Abstract][Full Text] [Related]
8. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
[TBL] [Abstract][Full Text] [Related]
9. Covariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms.
Cashin K; Sterjovski J; Harvey KL; Ramsland PA; Churchill MJ; Gorry PR
PLoS One; 2014; 9(10):e109771. PubMed ID: 25313689
[TBL] [Abstract][Full Text] [Related]
10. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
Jensen MA; Li FS; van 't Wout AB; Nickle DC; Shriner D; He HX; McLaughlin S; Shankarappa R; Margolick JB; Mullins JI
J Virol; 2003 Dec; 77(24):13376-88. PubMed ID: 14645592
[TBL] [Abstract][Full Text] [Related]
11. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
12. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
13. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5.
Isaka Y; Sato A; Miki S; Kawauchi S; Sakaida H; Hori T; Uchiyama T; Adachi A; Hayami M; Fujiwara T; Yoshie O
Virology; 1999 Nov; 264(1):237-43. PubMed ID: 10544150
[TBL] [Abstract][Full Text] [Related]
14. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
Polzer S; Dittmar MT; Schmitz H; Schreiber M
Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
[TBL] [Abstract][Full Text] [Related]
15. A virus-envelope paired competitive assay to study entry efficiency of human immunodeficiency virus type 1 in vitro.
Schwalbe B; Hauser H; Schreiber M
J Virol Methods; 2014 Sep; 205():91-8. PubMed ID: 24859049
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.
Cardozo T; Kimura T; Philpott S; Weiser B; Burger H; Zolla-Pazner S
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):415-26. PubMed ID: 17411375
[TBL] [Abstract][Full Text] [Related]
17. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
[TBL] [Abstract][Full Text] [Related]
18. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.
Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB
Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692
[TBL] [Abstract][Full Text] [Related]
19. Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.
Hongjaisee S; Braibant M; Barin F; Ngo-Giang-Huong N; Sirirungsi W; Samleerat T
AIDS Res Hum Retroviruses; 2017 Sep; 33(9):946-951. PubMed ID: 28497977
[TBL] [Abstract][Full Text] [Related]
20. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
Nabatov AA; Pollakis G; Linnemann T; Kliphius A; Chalaby MI; Paxton WA
J Virol; 2004 Jan; 78(1):524-30. PubMed ID: 14671134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
